Simon Property Group Inc
Change company Symbol lookup
Select an option...
SPG Simon Property Group Inc
JNJ Johnson & Johnson
SPHD Invesco S&P 500® High Dividend Low Volatility ETF
WMT WALMART STORES INC
BROG Brooge Holdings Ltd
EMRAF Emera Inc
PPL PPL Corp
PG Procter & Gamble Co
CLOU Global X Cloud Computing ETF Global X Cloud Computing ETF
GDRX Goodrx Holdings Inc
Go

Real Estate : Equity Real Estate Investment Trusts (REITs) | Mid Cap Value
Company profile

Simon Property Group, Inc. is a self-administered and self-managed real estate investment trust (REIT). The Company owns, develops and manages retail real estate properties, which consist primarily of malls, Premium Outlets and The Mills. Simon Property Group, L.P. (Operating Partnership), is the Company's partnership subsidiary that owns all of its real estate properties and other assets. As of December 31, 2016, the Company owned or held an interest in 206 income-producing properties in the United States, which consisted of 108 malls, 67 Premium Outlets, 14 Mills, four lifestyle centers, and 13 other retail properties in 37 states and Puerto Rico. As of December 31, 2016, it had redevelopment and expansion projects, including the addition of anchors, big box tenants, and restaurants, underway at 27 properties in the United States and it had one outlet and one other retail project under development.

Postmarket

Last Trade
Delayed
$83.22
0.65 (0.79%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$82.57
Day's Change
-2.98 (-3.48%)
Bid
--
Ask
--
B/A Size
--
Day's High
86.90
Day's Low
82.40
Volume
(Light)
Volume:
6,983,693

10-day average volume:
8,774,595
6,983,693

Oncology Market Size 2020 Particularly Prone To Disruption During Pandemic In The Global Oncology Market

6:00 am ET October 6, 2020 (Globe Newswire) Print

(Oncology Drugs Companies Included: F. Hoffmann-La Roche AG, Novartis AG, Bristol-Myers Squibb Company, Merck & Co., Inc., Johnson & Johnson)

The global oncology/cancer drugs market size reached a value of nearly $167.9 billion in 2019, having increased at a compound annual growth rate (CAGR) of 9.8% since 2015. The oncology market size 2020 is expected to decline from $167.9 billion in 2019 to $149.9 billion in 2020 at a rate of -11%. The decline is mainly due to lockdown and social distancing norms imposed by various countries and economic slowdown across countries owing to the COVID-19 outbreak and the measures to contain it. The market is then expected to grow slightly from $201.1 billion in 2021 to $284.5 billion in 2023 at a CAGR of 9.7%. North America has the largest cancer drug market share, accounting for 41.2% of the total market.

The Business Research Company's report titled Oncology Drugs Market - Opportunities And Strategies - Global Forecast To 2030 covers major oncology drugs companies, oncology drugs market share by company, oncology drugs manufacturers, oncology drugs infrastructure market size, and oncology drugs market forecasts. The report also covers the global oncology drugs market and its segments. The cancer market by type is segmented into drugs for lung cancer, pancreatic cancer, breast cancer, prostate cancer, ovarian cancer, colorectal cancer, gastric cancer, kidney cancer, brain tumor, thyroid cancer, skin cancer, bladder cancer, cervical cancer, blood cancer and others, by drug class type into targeted therapy, immunotherapy (biologic therapy), chemotherapy and hormonal therapy, by distribution channel into hospital pharmacies, retail pharmacies/drug stores and others, by route of administration into oral, parental and others, by drug classification into branded drugs and generic drugs.

Request For A Sample Of The Global Oncology Drugs Market Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3440&type=smp

Companies in the oncology drugs market are increasing their product innovation through strategic collaborations. To sustain in the increasingly competitive market, organizations are developing innovative products as well as sharing skills and expertise with other such enterprises. While oncology drug companies have long collaborated with each other as well as with academic and research institutions in this market by way of partnerships, in or out licensing deals, this trend has been increasing over the recent years.

New technologies are being implemented in the cancer drug market, such as artificial intelligence in the research and development process, as well as 3D printing devices to mimic the human body for trials and testing of the drugs developed. Companies are also investing in technologies to develop next generation biologics such as antibody drug conjugates, bispecifics, fusion proteins, cell and gene therapy that will be more effective as they are expected to have better potency against the target disease as well as have the ability to treat more than one aspect of the disease. Over the last few years, there has been a significant rise in accelerated approval of cell and gene therapies for cancer treatment by regulatory bodies across the globe. CRISPR technology can be used to discover the non-coding cancer genome. CRISPR-Cas9 genome editing reduces the processing associated with the generation of cell line and animal models of cancer and complex generations. Thus, it generates a better cancer model for target validation and drug evaluation. CRISPR-Cas9 is accelerating the different stages of oncology drug discovery including target identification, validation and deconvolution, drug synthesis, assessment of drug sensitivity and resistance.

With innovation through technology and rising focus on development of new drugs, the oncology drugs market trends ought to bring advances in cancer therapies in the forecasted period.

Oncology Drugs Market - Opportunities And Strategies - Global Forecast To 2030 is one of a series of new reports from The Business Research Company that provide oncology drugs market overviews, oncology drugs market analyze and forecast oncology drugs market size and growth for the whole market, oncology drugs market segments and oncology drugs market geographies, oncology drugs market trends, oncology drugs market drivers, oncology drugs market restraints, oncology drugs market leading competitors' revenues, profiles and market shares in over 1,000 industry reports, covering over 2,500 market segments and 60 geographies.

The report also gives in-depth analysis of the impact of COVID-19 on the market. The reports draw on 150,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders. A highly experienced and expert team of analysts and modelers provides market analysis and forecasts. The reports identify top countries and segments for opportunities and strategies based on market trends and leading competitors' approaches.

Here Is A List Of Similar Reports By The Business Research Company:

Clinical Oncology Next Generation Sequencing Global Market Report 2020-30: COVID 19 Growth and Change

Interventional Oncology Devices Global Market Report 2020-30: COVID 19 Growth and Change

Cancer Diagnostics Global Market Report 2020-30: COVID 19 Growth And Change

Interested to know more about The Business Research Company?

The Business Research Company is a market intelligence firm that excels in company, market, and consumer research. Located globally it has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services, chemicals, and technology.

The World's Most Comprehensive Database

The Business Research Company's flagship product, Global Market Model, is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps.

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 8897263534

Americas: +1 315 623 0293

Email: info@tbrc.info

Follow us on LinkedIn: https://in.linkedin.com/company/the-business-research-company

Follow us on Twitter: https://twitter.com/tbrc_info

https://ml.globenewswire.com/media/3bf07720-8041-4b6e-84f3-8c3f28854315/small/the-business-research-company-horizontal-logo-2-png.png

comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.